Impact of Blood Salvage Therapy on Outcomes After Oncologic Liver Surgery
- Conditions
- Liver Neoplasms
- Interventions
- Procedure: Blood salvage therapy
- Registration Number
- NCT05164406
- Lead Sponsor
- Université de Sherbrooke
- Brief Summary
A before and after trial comparing the systematic use of blood salvage therapy with leucocyte filter during oncologic liver resections. Recurrence, survival, allogenic transfusion rates and surgical outcomes are compared with a representative historic cohort.
- Detailed Description
Blood salvage therapy in oncologic liver surgery is seldom used based on unproven concerns about the safety of the technique regarding potential cancer dissemination or recurrence. Nevertheless, the technique has proven advantages in other surgical settings regarding the allogenic transfusion outcomes. Allogenic blood transfusion has been scientifically proven to worsen prognosis in oncologic surgery. This study compares a cohort of patients systematically exposed the blood salvage therapy to one comparable cohort without the therapy and outcomes regarding transfusion rates, post-operative Hb measurement, recurrence, overall survival, and post-operative adverse events.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 106
- Adult Oncologic liver surgery scheduled in our institution
- Condition precluding consent for trial Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description With blood salvage Blood salvage therapy Patients undergoing oncologic liver surgery with systematic use of blood salvage therapy
- Primary Outcome Measures
Name Time Method Recurrence free survival 18 months Overall survival 18 months Transfusion Up to 30 days after surgery Allogenic blood products requirements
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre Hospitalier Universitaire de Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada